Company: CERO
Filing Date: 2025-04-15
Form Type: 10-K
Source: 0001213900-25-032134
Chunk: 1903

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-04-15
Form: 10-K
Item: Item 1B
Chunk 1903
---
 to exercise their Series A Preferred Warrants for cash (the “December 2024 Common Warrants”). The December 2024
Common Warrants are initially exercisable for cash at an initial exercise price equal to $5.61 (as adjusted for stock splits, stock dividends,
stock combinations, recapitalizations and similar events).

The December 2024 Common
Warrants are exercisable beginning six months after the issuance date (the “Initial Exercisability Date”) and expiring on
the third anniversary of the Initial Exercisability Date. The December 2024 Common Warrants require “buy-in” payments to be
made by us for failure to deliver any shares of Common Stock issuable upon exercise.

If at the time of exercise
of the December 2024 Common Warrants, there is no effective registration statement registering the shares of the Common Stock underlying
the December 2024 Common Warrants, such warrants may be exercised on a cashless basis pursuant to their terms.

If we issue options, convertible
securities, warrants, shares, or similar securities to holders of Common Stock, each holder of December 2024 Common Warrants has the right
to acquire the same as if the holder had exercised its December 2024 Common Warrants. The holders of December 2024 Common Warrants are
entitled to receive any dividends paid or distributions made to our holders of Common Stock on an “as if converted” basis.

The December 2024 Common
Warrants prohibit us from entering into specified fundamental transactions unless the successor entity assumes all of our obligations
under the December 2024 Common Warrants under a written agreement before the transaction is completed. Upon specified corporate events,
a holder of December 2024 Common Warrants will thereafter have the right to receive upon an exercise such shares, securities, cash, assets
or any other property whatsoever which the holder would have been entitled to receive upon the happening of the applicable corporate event
had the December 2024 Common Warrants been exercised immediately prior to the applicable corporate event. Upon the consummation of any
Fundamental Transaction, the Company shall exchange the December 2024 Common Warrants for consideration equal to the Black Scholes Value
of such portion of the December 2024 Common Warrants subject to exchange (collectively, the “Aggregate Black Scholes Value”)
in the form of, at the Company’s election (such election to pay in cash or by delivery of the Rights (as defined below), a “Consideration